Shukla Sath
SEC CIK 1782817 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| SPRO | Spero Therapeutics, Inc. | CFO | 1.89M | — | $305.7K | 13 | 2021-08-26 | 2025-02-05 |
Most active insiders at SPRO, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Rajavelu Esther | See Remarks | — | $406.8K |
| 2 | Keutzer Timothy | COO | — | $145.2K |
| 3 | Tregoning Kathleen | Dir | — | — |
| 4 | Zack Debra | Chief Medical Off | — | — |
| 5 | Smith Cynthia | Dir | — | — |
| 6 | Jackson Scott Thomas | Dir | — | — |
| 7 | VINK PATRICK V.J.J. | Dir | — | — |
| 8 | Deshpande Milind | Dir | — | — |
| 9 | Pottage John C Jr | Dir | — | — |
| 10 | THOMAS FRANK E | Dir | — | — |
Shukla Sath made no open-market trades at SPRO in the last 12 months.
Transactions 13
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-02-05 | 2025-02-05 | SPRO | Spero Therapeutics, Inc. | Shukla Sath | CEO, Pres | S - Sale | $0.78 | -155.3K | 1.89M | -8% | -$121.2K |
| 2025-02-05 | 2025-02-03 | SPRO | Spero Therapeutics, Inc. | Shukla Sath | CEO, Pres | A - Grant | $0.00 | +751.4K | 1.89M | +66% | $0 | |
| 2024-08-29 | 2024-08-27 | SPRO | Spero Therapeutics, Inc. | Shukla Sath | CEO, Pres | S - Sale | $1.35 | -2,757 | 1.14M | -0.2% | -$3,722 | |
| M | 2024-08-06 | 2024-08-02+ | SPRO | Spero Therapeutics, Inc. | Shukla Sath | CEO, Pres | S - Sale | $1.31 | -32.4K | 1.14M | -3% | -$42.6K |
| T | 2024-02-05 | 2024-02-01 | SPRO | Spero Therapeutics, Inc. | Shukla Sath | CEO, Pres, Dir | A - Grant | $0.00 | +679.5K | 1.25M | +119% | $0 |
| MT | 2024-02-05 | 2024-02-02+ | SPRO | Spero Therapeutics, Inc. | Shukla Sath | CEO, Pres, Dir | S - Sale | $1.42 | -76.0K | 1.22M | -6% | -$107.7K |
| MT | 2023-08-30 | 2023-08-28+ | SPRO | Spero Therapeutics, Inc. | Shukla Sath | CEO, Pres, Dir | S - Sale | $1.29 | -6,017 | 576.7K | -1% | -$7,748 |
| 2023-08-03 | 2023-08-01 | SPRO | Spero Therapeutics, Inc. | Shukla Sath | CEO, Pres, Dir | A - Grant | $0.00 | +266.0K | 578.5K | +85% | $0 | |
| 2023-02-03 | 2023-02-02 | SPRO | Spero Therapeutics, Inc. | Shukla Sath | CFO | S - Sale | $1.83 | -9,504 | 312.5K | -3% | -$17.4K | |
| 2023-02-03 | 2023-02-01 | SPRO | Spero Therapeutics, Inc. | Shukla Sath | CFO | A - Grant | $0.00 | +266.0K | 322.0K | +474% | $0 | |
| 2022-08-30 | 2022-08-29 | SPRO | Spero Therapeutics, Inc. | Shukla Sath | CFO | S - Sale | $0.89 | -6,017 | 56.1K | -10% | -$5,355 | |
| D | 2022-02-03 | 2022-02-01 | SPRO | Spero Therapeutics, Inc. | Shukla Sath | CFO | A - Grant | $0.00 | +38.0K | 62.1K | +158% | $0 |
| 2021-08-30 | 2021-08-26 | SPRO | Spero Therapeutics, Inc. | Shukla Sath | CFO | A - Grant | $0.00 | +24.1K | 24.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations